JP3487611B2 - 二重作用抑制剤 - Google Patents

二重作用抑制剤

Info

Publication number
JP3487611B2
JP3487611B2 JP11587493A JP11587493A JP3487611B2 JP 3487611 B2 JP3487611 B2 JP 3487611B2 JP 11587493 A JP11587493 A JP 11587493A JP 11587493 A JP11587493 A JP 11587493A JP 3487611 B2 JP3487611 B2 JP 3487611B2
Authority
JP
Japan
Prior art keywords
hydrogen
oxo
ethyl acetate
mmol
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP11587493A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0656790A (ja
Inventor
ドナルド・エス・カラネウスキ
ジョエル・シー・バリッシュ
エドワード・ダブリュー・ペトリロ・ジュニア
ジェフリー・エイ・ロブル
デニス・イー・リオノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Publication of JPH0656790A publication Critical patent/JPH0656790A/ja
Application granted granted Critical
Publication of JP3487611B2 publication Critical patent/JP3487611B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
    • C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
JP11587493A 1992-05-18 1993-05-18 二重作用抑制剤 Expired - Fee Related JP3487611B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88466492A 1992-05-18 1992-05-18
US884664 1992-05-18

Publications (2)

Publication Number Publication Date
JPH0656790A JPH0656790A (ja) 1994-03-01
JP3487611B2 true JP3487611B2 (ja) 2004-01-19

Family

ID=25385092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP11587493A Expired - Fee Related JP3487611B2 (ja) 1992-05-18 1993-05-18 二重作用抑制剤

Country Status (28)

Country Link
EP (2) EP0783002A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3487611B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR100288722B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1039008C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE162800T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU659550B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR1101081A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2096460C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY2093B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ289824B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69316717T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0599444T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2111712T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI103337B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3026665T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1003597A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU217078B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL105729A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9302876A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY111370A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO304372B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ247642A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL173036B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2124503C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG54138A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK283556B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW290544B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA933461B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430145A (en) * 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
ES2106112T3 (es) * 1991-09-27 1997-11-01 Merrell Pharma Inc Derivados de indano-2-mercaptoacetilamida con una actividad inhibidora de encefalinasa y de ace.
CA2078759C (en) * 1991-09-27 2003-09-16 Alan M. Warshawsky Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
US5455242A (en) * 1991-09-27 1995-10-03 Merrell Dow Pharmaceuticals Inc. Carboxyalkyl tricyclic derivatives useful as inhibitors of enkephalinase and ace
US5457196A (en) * 1991-09-27 1995-10-10 Merrell Dow Pharmaceuticals Inc. 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5663166A (en) * 1991-10-18 1997-09-02 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
DE69317764T2 (de) * 1992-02-14 1998-07-30 Merrell Pharmaceuticals Inc., Cincinnati, Ohio Aminoacetylmercaptoacetylamid derivate mit enkephalinase- und ace-hemmwirkung
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
US5420271A (en) * 1992-08-24 1995-05-30 Merrell Dow Pharmaceuticals, Inc. 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
GB9310075D0 (en) * 1993-05-17 1993-06-30 Fujisawa Pharmaceutical Co New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
US5679671A (en) * 1993-06-11 1997-10-21 Eisai Co., Ltd. Amino acid derivative
ES2076096B1 (es) * 1993-07-14 1996-03-16 Squibb & Sons Inc Compuestos inhibidores de la enzima convertidora de angiotensinas y dela endopeptidasa neutra, y metodos para prepararlos.
US5525723A (en) * 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
ATE209205T1 (de) * 1994-02-14 2001-12-15 Merrell Pharma Inc Indan-2-mercaptoacetylamid disulfidderivate als enkephalinase inhibitoren
AU687507B2 (en) * 1994-02-14 1998-02-26 Merrell Pharmaceuticals Inc. Mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ace
CN1100785C (zh) * 1994-02-14 2003-02-05 默里尔药物公司 1,3,4,5－四氢苯并[c]氮杂䓬－3－酮二硫化物衍生物及方法
US5530013A (en) * 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
FI963167A7 (fi) * 1994-02-14 1996-08-13 Merrell Pharma Inc Enkefalinaasin ja ACE:n ihibiittoreina käyttökelpoisia uusia 2-substit uoituja indaani-2-merkaptoasetyyliamididisulfidijohdannaisia
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
HUP9774624A2 (en) * 1994-03-24 1997-01-28 Merrell Pharma Inc Hypocholesterolemic, antiatheroclerotic and hypotriglyceridemic condensed benzazepine mercaptoacetylamide disulfide derivatives
WO1995025532A1 (en) * 1994-03-24 1995-09-28 Merrell Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic aminoacetylmercapto derivatives
NZ287557A (en) * 1994-07-18 1997-04-24 Eisai Co Ltd 6-amino-3-carboxy-5-oxothiazolo[3,2-a]azepine derivatives n-acylated by an alpha-substituted-w-mercapto carboxylic acid
CA2297134C (en) * 1994-12-21 2004-02-10 Hoechst Marion Roussel, Inc. A novel process for preparing intermediates or inhibitors of enkephalinase and angiotensin converting enzyme and intermediates thereof
US5641880A (en) * 1994-12-21 1997-06-24 Hoechst Marion Roussel, Inc. Processes for preparing intermediates of inhibitors of enkephalinase and angiotensin converting enzyme and intermediates thereof
CN1049830C (zh) * 1995-01-13 2000-03-01 李勤 一种治疗癌痛的热力敷
US5587375A (en) * 1995-02-17 1996-12-24 Bristol-Myers Squibb Company Azepinone compounds useful in the inhibition of ACE and NEP
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5877313A (en) 1995-05-17 1999-03-02 Bristol-Myers Squibb Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP
US5650408A (en) * 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
US5635504A (en) * 1995-06-07 1997-06-03 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
WO1997017972A1 (fr) * 1995-11-13 1997-05-22 Eisai Co., Ltd. Composition abaissant le taux de cholesterol
US6777550B1 (en) 1996-04-12 2004-08-17 Bristol-Myers Squibb Company N-formyl hydroxylamine containing compounds useful as ACE inhibitors and/or NEP inhibitors
EP0894003A4 (en) * 1996-04-12 2000-10-04 Bristol Myers Squibb Co N-FORMYL HYDROXYLAMINE-BASED COMPOUNDS SUITABLE AS INCEPTIENTS OF THE ACE ENZYME AND / OR ENDOPEPTIDASE NEP
US6117896A (en) * 1997-02-10 2000-09-12 Molecumetics Ltd. Methods for regulating transcription factors
US6340752B1 (en) * 1998-01-06 2002-01-22 Bristol-Myers Squibb Co. Deprotection and recrystallization processes
JP4588877B2 (ja) 1998-06-17 2010-12-01 ブリストル−マイヤーズ スクイブ カンパニー Ａｄｐ−受容体抗血小板物質と抗高血圧薬の組合せ投与による脳梗塞の予防
US6262080B1 (en) 1998-12-31 2001-07-17 Avantis Pharmaceuticals Inc. 3-(thio-substitutedamido)-lactams useful as inhibitors of matrix metalloproteinase
CA2358955A1 (en) * 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
US6770640B1 (en) 1998-12-31 2004-08-03 Aventis Pharmaceuticals Inc. 1-Carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of MMP-12
US7094926B2 (en) 2000-01-25 2006-08-22 Kaneka Corporation Process for producing optically active carboxylic acid substituted in 2-position
US6509330B2 (en) 2000-02-17 2003-01-21 Bristol-Myers Squibb Company Hydroxamic acid containing compounds useful as ACE inhibitors and/or NEP inhibotors
DE10020818A1 (de) * 2000-04-28 2001-10-31 Degussa 2,6-Diamino-6-methyl-heptansäure und Derivate, Verfahren zu deren Herstellung und deren Verwendung
ATE309977T1 (de) 2000-09-29 2005-12-15 Bristol Myers Squibb Co Dynamische trennung von isomeren und getrennte isomere
GB0119305D0 (en) 2001-04-12 2001-10-03 Aventis Pharma Gmbh Mercaptoacetylamide derivatives,a process for their preparation and their use
EP1395560A1 (en) * 2001-05-23 2004-03-10 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
WO2003043624A1 (en) 2001-11-16 2003-05-30 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
EP1482941A4 (en) 2002-02-14 2006-04-12 Myriad Genetics Inc BETA-SHEET MIMETIKA AND COMPOSITION AND RELEVANT PROCEDURES
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US7045653B2 (en) 2002-12-23 2006-05-16 Pfizer, Inc. Pharmaceuticals
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP1773348A4 (en) * 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc TETRA PEPTIDE ANALOGS
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
WO2008057857A1 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
EP2089389A2 (en) 2006-11-01 2009-08-19 Bristol-Myers Squibb Company Heterocyclic compounds as modulators of glucocorticoid receptor, ap-1, and/or nf-kappa-b activity
WO2008057862A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
CN103601792B (zh) 2007-06-04 2016-06-29 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP4718534B2 (ja) * 2007-11-09 2011-07-06 カルピス株式会社 Ｆｉｓｃｈｅｒ比低下抑制剤
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009158380A1 (en) 2008-06-24 2009-12-30 Bristol-Myers Squibb Company Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2434895A4 (en) 2009-05-13 2013-08-07 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
ES2745819T3 (es) 2014-08-07 2020-03-03 Intra Cellular Therapies Inc Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
WO2017109724A1 (en) 2015-12-21 2017-06-29 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
CN106674228B (zh) * 2016-12-09 2018-12-04 河南农业大学 多元杂环化合物及其制备方法和用途
US11839614B2 (en) 2018-01-31 2023-12-12 Intra-Cellular Therapies, Inc. Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
CA3192763A1 (en) * 2020-09-17 2022-03-24 Novartis Ag Compounds and compositions as sppl2a inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105776A (en) 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4339600A (en) 1976-05-10 1982-07-13 E. R. Squibb & Sons, Inc. Compounds for alleviating angiotensin related hypertension
US4587050A (en) 1980-08-18 1986-05-06 Merck & Co., Inc. Substituted enantholactam derivatives as antihypertensives
US4629787A (en) 1980-08-18 1986-12-16 Merck & Co., Inc. Substituted caprolactam derivatives as antihypertensives
US4415496A (en) 1981-03-23 1983-11-15 Merck & Co., Inc. Bicyclic lactams
US4587238A (en) 1981-07-06 1986-05-06 Merck & Co., Inc. Substituted caprylolactam derivatives as anti-hypertensives
EP0094283B1 (fr) 1982-05-04 1985-11-21 Lipha, Lyonnaise Industrielle Pharmaceutique Forme médicamenteuse de théophylline à action prolongée
US4873235A (en) 1982-06-01 1989-10-10 Merck & Co., Inc. Benzofused lactams as antihypertensives
US4473575A (en) 1982-07-19 1984-09-25 Ciba-Geigy Corporation 3-Amino-(1)-benzazepin-2-one-1-alkanoic acids
US4465679A (en) 1983-01-31 1984-08-14 Usv Pharmaceutical Corporation 1,2-Diaza-3-one compounds, their use in treating hypertension and pharmaceutical compositions thereof
US4477464A (en) 1983-02-10 1984-10-16 Ciba-Geigy Corporation Hetero-benzazepine derivatives and their pharmaceutical use
US4470988A (en) 1983-02-10 1984-09-11 Ciba-Geigy Corporation Benzazocinone and benzazoninone derivatives, and their pharmaceutical use
US4460579A (en) 1983-02-28 1984-07-17 E. R. Squibb & Sons, Inc. Thiazine and thiazepine containing compounds
US4711884A (en) 1983-02-28 1987-12-08 E. R. Squibb & Sons, Inc. Thiazine and thiazepine containing compounds
US4617301A (en) * 1983-06-22 1986-10-14 Merck & Co., Inc. Sulfoxide and sulfone derivatives of bicyclic lactams as antihypertensives
US4539150A (en) 1983-06-29 1985-09-03 Mitsui Toatsu Chemicals, Inc. Benzothiazepine derivatives and their methods of preparation
IL72523A (en) 1983-08-12 1988-06-30 Takeda Chemical Industries Ltd 3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives,their production and pharmaceutical compositions containing them
DE3402310A1 (de) 1984-01-24 1985-07-25 Bayer Ag, 5090 Leverkusen Harte, geschlossenzellige, flammfeste polyurethanschaumstoffe
SU1435151A3 (ru) 1984-04-10 1988-10-30 Санкио Компани Лимитед (Фирма) Способ получени производных пергидротиазепина или их кислотно-аддитивных фармацевтически приемлемых солей
JPH0637473B2 (ja) 1985-10-11 1994-05-18 三共株式会社 ラクタム化合物
EP0254032A3 (en) * 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
US4801609B1 (en) 1987-03-27 1993-11-09 Mercapto-acylamino acid antihypertensives
US4767756A (en) * 1987-07-17 1988-08-30 E. R. Squibb & Sons, Inc. 3-substituted benzazepines
US4771047A (en) * 1987-07-27 1988-09-13 E. R. Squibb & Sons, Inc. Benzazepine derivatives
JP3054738B2 (ja) * 1988-07-22 2000-06-19 武田薬品工業株式会社 チアゾロ［５，４―ｂ］アゼピン誘導体
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace

Also Published As

Publication number Publication date
AU659550B2 (en) 1995-05-18
NO931795L (no) 1993-11-19
ES2111712T3 (es) 1998-03-16
AU3862793A (en) 1993-11-25
SG54138A1 (en) 1998-11-16
KR100277453B1 (ko) 2000-12-15
AU674629B2 (en) 1997-01-02
RU2124503C1 (ru) 1999-01-10
MY111370A (en) 1999-12-31
EP0599444B1 (en) 1998-01-28
IL105729A0 (en) 1993-09-22
IL105729A (en) 1998-01-04
CA2096460C (en) 2004-03-16
JPH0656790A (ja) 1994-03-01
HU9301448D0 (en) 1993-09-28
MX9302876A (es) 1993-12-01
ATE162800T1 (de) 1998-02-15
HU217078B (hu) 1999-11-29
DE69316717D1 (de) 1998-03-05
HK1003597A1 (en) 1998-10-30
CN1084849A (zh) 1994-04-06
CZ93693A3 (en) 1993-12-15
DE69316717T2 (de) 1998-08-27
KR100288722B1 (ko) 2001-05-02
PL298988A1 (en) 1994-01-24
CN1039008C (zh) 1998-07-08
CY2093B1 (en) 2002-04-05
EP0783002A2 (en) 1997-07-09
DK0599444T3 (da) 1998-09-21
CZ289824B6 (cs) 2002-04-17
EP0599444A1 (en) 1994-06-01
KR930023349A (ko) 1993-12-18
FI932249L (fi) 1993-11-19
GR3026665T3 (en) 1998-07-31
FI932249A0 (fi) 1993-05-18
PL173036B1 (pl) 1998-01-30
FI103337B (fi) 1999-06-15
FI103337B1 (fi) 1999-06-15
BR1101081A (pt) 2000-03-28
EP0783002A3 (en) 1997-07-30
NO304372B1 (no) 1998-12-07
AU2852595A (en) 1995-10-19
SK49993A3 (en) 1994-08-10
HUT68391A (en) 1995-06-28
ZA933461B (en) 1993-12-14
SK283556B6 (sk) 2003-09-11
NZ247642A (en) 1995-09-26
TW290544B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1996-11-11
NO931795D0 (no) 1993-05-18
CA2096460A1 (en) 1993-11-19

Similar Documents

Publication Publication Date Title
JP3487611B2 (ja) 二重作用抑制剤
US5552397A (en) Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
HK1003597B (en) Dual action inhibitors
US5670699A (en) Process for preparing amino acid esters useful as intermediates for compounds containing a fused bicyclic ring
EP0750631B1 (en) Novel mercaptoacetylamido 1,3,4,5-tetrahydro-benzo(c)azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace
JPH08502746A (ja) エンケファリナーゼ及びａｃｅの阻害剤として有用な新規なメルカプトアセチルアミド二環式ラクタム誘導体類
US5856476A (en) Processes for preparing azepiones useful as intermediates in the preparation of inhibitors of angiotensin converting enzyme and neutral endopeptidase
EP0728746B1 (en) Azepinone compounds useful in the inhibition of ACE and NEP
JP2003513958A (ja) β−アミロイドペプチド放出および／またはその合成を阻害するために有用なβ−アミノ酸化合物
JP3596778B2 (ja) エンケファリナーゼ及びａｃｅの阻害剤として有用な、新規なメルカプトアセチルアミドジスルフィド誘導体類
HK1001206A (en) Dual action inhibitors
JP3561753B2 (ja) エンケファリナーゼ及びａｃｅの阻害剤として有用な、新規な２−置換インダン−２−メルカプトアセチルアミドジスルフィド誘導体類
HU218482B (hu) Tio- és karbonil-amino-csoportot tartalmazó oldallánccal helyettesített heterociklusos karbonsavszármazékok és az ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20031007

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20071031

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081031

Year of fee payment: 5

LAPS Cancellation because of no payment of annual fees